PARP1 is a validated ovarian cancer target, with new opportunity concentrated in biomarker precision and combination strategy.

AR is one of oncology’s most validated targets, but new value requires resistance-focused or modality-differentiated strategy.

ESR1 is a foundational breast cancer target with continuing opportunity in endocrine resistance and oral degrader strategies.

PIK3CA is a validated breast cancer target with high clinical relevance and intense safety/differentiation pressure.

MET is a high-interest NSCLC target, but strategic value depends on biomarker precision and indication-specific competitive mapping.

ROS1 is a validated but specialized NSCLC target where precision evidence and differentiation matter more than raw target popularity.

BRAF is a highly validated melanoma target, but competition is mature and strategy must focus on resistance, CNS, or combination innovation.

RET is a validated precision-oncology target with meaningful remaining development space, especially in resistance and earlier lines.

ALK is a high-validation, high-competition target. MCP-derived evidence supports continued strategic interest, but only with clear differentiation.

A visual FGFR2 target evaluation report for cholangiocarcinoma, generated from PatSnap Target & Disease MCP and Clinical Trials MCP data, covering biology, validation evidence, competition, IP considerations, and R&D strategy.

A visual CD38 target evaluation report for multiple myeloma, generated from PatSnap Target & Disease MCP and Clinical Trials MCP data, covering biology, validation evidence, competition, IP considerations, and R&D strategy.

A visual CD47 target evaluation report for AML, generated from PatSnap Target & Disease MCP and Clinical Trials MCP data, covering biology, validation evidence, competition, IP considerations, and R&D strategy.